# Structure Therapeutics' Oral GLP-1 Shows 15% Weight Loss, Positioning It Against Eli Lilly and Novo Nordisk - Date: 2026-03-16 - Category: Biotech & Life Sciences **Aleniglipron data positions Structure as third player in race for oral obesity drugs** --- In the heated race to develop oral GLP-1 drugs for obesity, a third contender is emerging. Structure Therapeutics reported Phase 2 data this week for aleniglipron, its once-daily oral small molecule GL... ---